Zobrazeno 1 - 3
of 3
pro vyhledávání: '"A. Yu. Povyshev"'
Autor:
E. I. Kovalenko, E. V. Artamonova, L. V. Bolotina, L. A. Zhiliaeva, D. M. Ponomarenko, E. V. Karabina, G. Z. Mukhametshina, A. I. Khasanova, E. Yu. Ratner, A. R. Safarova, A. G. Manikhas, N. O. Popova, I. V. Evstigneeva, L. Yu. Vladimirova, L. V. Kramskaya, T. V. Karandeeva, I. R. Suslova, O. V. Romanchuk, V. E. Shikina, A. Yu. Povyshev, M. A. Osipov, E. M. Cherniakova, A. S. Dergunov, M. V. Volkonskiy, I. S. Chernov, I. E. Shumskaya, M. M. Fael, V. I. Garifullina, I. E. Gudkova
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 36-46 (2021)
Introduction. The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further treatment, as well as the opti
Externí odkaz:
https://doaj.org/article/ddfb182fcf6247f0b4a7bd188e53d850
Autor:
N. S. Besova, T. A. Titova, Е. V. Artamonova, A. A. Tryakin, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukalchuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, I. S. Stilidi
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 165-174 (2020)
Background. Ramucirumab is a monoclonal antibody that inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). The study is aimed to analyse prognostic factors for survival in patients with disseminated gastric cancer who received ramucir
Externí odkaz:
https://doaj.org/article/c36b27f6439d4e80b0427ab6e064acee
Autor:
N. S. Besova, T. A. Titova, E. V. Artamonova, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukal’chuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, A. A. Tryakin, I. S. Stilidi
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 104-113 (2019)
Introduction: Ramucirumab (Ram), a human IgG 1 antibody against vascular endothelial growth factor receptor 2. This multicenter retrospective study aims to reviewed the results of Ram-based therapy as second-line treatment in patients with advanced g
Externí odkaz:
https://doaj.org/article/585c4f001e1d4aa6b26c7d34d605422b